- Home
- SOWG vs NERV Comparison
SOWG vs NERV Comparison
Compare SOWG & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- NERV
- Stock Information
- Founded
- SOWG 2010
- NERV 2007
- Country
- SOWG United States
- NERV United States
- Employees
- SOWG N/A
- NERV N/A
- Industry
- SOWG Packaged Foods
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- SOWG Consumer Staples
- NERV Health Care
- Exchange
- SOWG Nasdaq
- NERV Nasdaq
- Market Cap
- SOWG 10.7M
- NERV 12.0M
- IPO Year
- SOWG N/A
- NERV 2014
- Fundamental
- Price
- SOWG $0.69
- NERV $2.43
- Analyst Decision
- SOWG
- NERV Hold
- Analyst Count
- SOWG 0
- NERV 1
- Target Price
- SOWG N/A
- NERV $5.00
- AVG Volume (30 Days)
- SOWG 339.2K
- NERV 41.2K
- Earning Date
- SOWG 08-14-2025
- NERV 08-14-2025
- Dividend Yield
- SOWG N/A
- NERV N/A
- EPS Growth
- SOWG N/A
- NERV N/A
- EPS
- SOWG N/A
- NERV 1.48
- Revenue
- SOWG $9,271,376.00
- NERV N/A
- Revenue This Year
- SOWG $6.81
- NERV N/A
- Revenue Next Year
- SOWG N/A
- NERV N/A
- P/E Ratio
- SOWG N/A
- NERV $1.65
- Revenue Growth
- SOWG N/A
- NERV N/A
- 52 Week Low
- SOWG $0.51
- NERV $1.15
- 52 Week High
- SOWG $14.96
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- SOWG 42.44
- NERV 69.75
- Support Level
- SOWG $0.51
- NERV $2.21
- Resistance Level
- SOWG $1.05
- NERV $2.60
- Average True Range (ATR)
- SOWG 0.12
- NERV 0.14
- MACD
- SOWG -0.03
- NERV 0.06
- Stochastic Oscillator
- SOWG 32.59
- NERV 79.76
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.